Matt Dolan

Analyst Matt Dolan of Roth Capital upgrades CardioNet Inc (NASDAQ: BEAT) from "hold" to "buy." The target price for BEAT has been raised from $7 to $12. According to Roth Capital, despite uncertainty in BEAT’s reimbursement outlook, the company’s reimbursement will most likely stabilize or improve...

Analysts Matt Dolan and Matthew Pommer at Roth Capital Partners have released a report on the Medical Devices industry. Roth Capital Partners conducted a survey among C-level executives at small medical devices companies to gauge the expected impact of the healthcare reform. According to analysts...